Alnylam Cost Of Revenue vs Capex To Revenue Analysis

ALNY Stock

USD 253.74 0.39 0.15%

Alnylam Pharmaceuticals financial indicator trend analysis is way more than just evaluating Alnylam Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Alnylam Pharmaceuticals is a good investment. Please check the relationship between Alnylam Pharmaceuticals Cost Of Revenue and its Capex To Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alnylam Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.

Cost Of Revenue vs Capex To Revenue

Cost Of Revenue vs Capex To Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Alnylam Pharmaceuticals Cost Of Revenue account and Capex To Revenue. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Alnylam Pharmaceuticals' Cost Of Revenue and Capex To Revenue is -0.26. Overlapping area represents the amount of variation of Cost Of Revenue that can explain the historical movement of Capex To Revenue in the same time period over historical financial statements of Alnylam Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Alnylam Pharmaceuticals' Cost Of Revenue and Capex To Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost Of Revenue of Alnylam Pharmaceuticals are associated (or correlated) with its Capex To Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capex To Revenue has no effect on the direction of Cost Of Revenue i.e., Alnylam Pharmaceuticals' Cost Of Revenue and Capex To Revenue go up and down completely randomly.

Correlation Coefficient

-0.26

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Cost Of Revenue

Cost of Revenue is found on Alnylam Pharmaceuticals income statement and represents the costs associated with goods and services Alnylam Pharmaceuticals provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Capex To Revenue

The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.

Most indicators from Alnylam Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Alnylam Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alnylam Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide.At this time, Alnylam Pharmaceuticals' Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 7.1 M in 2024, whereas Sales General And Administrative To Revenue is likely to drop 0.41 in 2024.

	2021	2022	2023	2024 (projected)
Gross Profit	704.1M	868.6M	1.5B	1.6B
Total Revenue	844.3M	1.0B	1.8B	1.9B

Gross Profit Total Revenue

Alnylam Pharmaceuticals fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Property Plant Equipment	Short Long Term Debt Total	Other Liab	Current Deferred Revenue	Long Term Debt	Other Stockholder Equity
Total Assets		0.91	0.92	-0.1	0.95	0.6	-0.97	0.75	0.64	0.92	-0.36	0.72	0.98	0.78	0.96	0.87	0.39	0.91	0.96	0.99	0.96	0.78	0.7	0.43	0.85	0.98
Other Current Liab	0.91		0.83	-0.45	0.89	0.84	-0.96	0.59	0.5	0.84	-0.54	0.74	0.86	0.56	0.89	0.98	0.29	0.98	0.97	0.9	0.93	0.95	0.6	0.23	0.96	0.89
Total Current Liabilities	0.92	0.83		-0.13	0.96	0.59	-0.89	0.66	0.43	0.94	-0.22	0.58	0.85	0.7	0.91	0.79	0.48	0.86	0.92	0.87	0.92	0.68	0.79	0.7	0.74	0.89
Total Stockholder Equity	-0.1	-0.45	-0.13		-0.17	-0.71	0.26	0.05	0.2	-0.13	0.36	-0.26	0.01	0.29	-0.11	-0.56	0.03	-0.49	-0.31	-0.08	-0.19	-0.58	-0.2	0.27	-0.56	-0.02
Property Plant And Equipment Net	0.95	0.89	0.96	-0.17		0.64	-0.96	0.77	0.45	0.96	-0.28	0.65	0.88	0.73	0.95	0.85	0.45	0.9	0.96	0.91	0.98	0.73	0.72	0.54	0.82	0.95
Net Debt	0.6	0.84	0.59	-0.71	0.64		-0.71	0.27	0.03	0.59	-0.6	0.67	0.51	0.17	0.67	0.84	0.15	0.81	0.77	0.58	0.7	0.91	0.41	0.05	0.83	0.57
Retained Earnings	-0.97	-0.96	-0.89	0.26	-0.96	-0.71		-0.77	-0.55	-0.9	0.43	-0.76	-0.93	-0.74	-0.95	-0.93	-0.33	-0.96	-0.98	-0.96	-0.98	-0.84	-0.67	-0.33	-0.92	-0.97
Accounts Payable	0.75	0.59	0.66	0.05	0.77	0.27	-0.77		0.4	0.73	0.0	0.7	0.72	0.84	0.72	0.59	0.26	0.63	0.68	0.72	0.75	0.37	0.56	0.27	0.62	0.79
Cash	0.64	0.5	0.43	0.2	0.45	0.03	-0.55	0.4		0.37	-0.4	0.34	0.75	0.6	0.46	0.47	-0.01	0.48	0.47	0.71	0.47	0.44	0.37	0.09	0.48	0.62
Non Current Assets Total	0.92	0.84	0.94	-0.13	0.96	0.59	-0.9	0.73	0.37		-0.12	0.62	0.83	0.72	0.91	0.79	0.63	0.86	0.93	0.85	0.93	0.65	0.62	0.57	0.73	0.9
Non Currrent Assets Other	-0.36	-0.54	-0.22	0.36	-0.28	-0.6	0.43	0.0	-0.4	-0.12		-0.4	-0.41	-0.05	-0.34	-0.52	0.35	-0.46	-0.43	-0.43	-0.39	-0.71	-0.18	0.22	-0.57	-0.37
Other Assets	0.72	0.74	0.58	-0.26	0.65	0.67	-0.76	0.7	0.34	0.62	-0.4		0.71	0.55	0.71	0.74	0.02	0.74	0.73	0.73	0.71	0.72	0.48	0.03	0.8	0.73
Cash And Short Term Investments	0.98	0.86	0.85	0.01	0.88	0.51	-0.93	0.72	0.75	0.83	-0.41	0.71		0.8	0.93	0.81	0.26	0.85	0.9	0.99	0.9	0.74	0.68	0.37	0.81	0.97
Common Stock Shares Outstanding	0.78	0.56	0.7	0.29	0.73	0.17	-0.74	0.84	0.6	0.72	-0.05	0.55	0.8		0.72	0.51	0.33	0.57	0.66	0.78	0.72	0.38	0.52	0.46	0.5	0.82
Short Term Investments	0.96	0.89	0.91	-0.11	0.95	0.67	-0.95	0.72	0.46	0.91	-0.34	0.71	0.93	0.72		0.84	0.38	0.89	0.96	0.94	0.96	0.75	0.71	0.45	0.82	0.96
Non Current Liabilities Total	0.87	0.98	0.79	-0.56	0.85	0.84	-0.93	0.59	0.47	0.79	-0.52	0.74	0.81	0.51	0.84		0.24	0.99	0.93	0.86	0.88	0.94	0.62	0.17	0.99	0.83
Other Current Assets	0.39	0.29	0.48	0.03	0.45	0.15	-0.33	0.26	-0.01	0.63	0.35	0.02	0.26	0.33	0.38	0.24		0.33	0.4	0.28	0.38	0.11	0.17	0.49	0.11	0.34
Total Liab	0.91	0.98	0.86	-0.49	0.9	0.81	-0.96	0.63	0.48	0.86	-0.46	0.74	0.85	0.57	0.89	0.99	0.33		0.97	0.9	0.91	0.91	0.69	0.27	0.97	0.87
Property Plant And Equipment Gross	0.96	0.97	0.92	-0.31	0.96	0.77	-0.98	0.68	0.47	0.93	-0.43	0.73	0.9	0.66	0.96	0.93	0.4	0.97		0.93	0.98	0.87	0.69	0.38	0.9	0.94
Total Current Assets	0.99	0.9	0.87	-0.08	0.91	0.58	-0.96	0.72	0.71	0.85	-0.43	0.73	0.99	0.78	0.94	0.86	0.28	0.9	0.93		0.93	0.79	0.69	0.35	0.86	0.97
Property Plant Equipment	0.96	0.93	0.92	-0.19	0.98	0.7	-0.98	0.75	0.47	0.93	-0.39	0.71	0.9	0.72	0.96	0.88	0.38	0.91	0.98	0.93		0.79	0.67	0.42	0.85	0.97
Short Long Term Debt Total	0.78	0.95	0.68	-0.58	0.73	0.91	-0.84	0.37	0.44	0.65	-0.71	0.72	0.74	0.38	0.75	0.94	0.11	0.91	0.87	0.79	0.79		0.5	0.06	0.93	0.74
Other Liab	0.7	0.6	0.79	-0.2	0.72	0.41	-0.67	0.56	0.37	0.62	-0.18	0.48	0.68	0.52	0.71	0.62	0.17	0.69	0.69	0.69	0.67	0.5		0.54	0.63	0.64
Current Deferred Revenue	0.43	0.23	0.7	0.27	0.54	0.05	-0.33	0.27	0.09	0.57	0.22	0.03	0.37	0.46	0.45	0.17	0.49	0.27	0.38	0.35	0.42	0.06	0.54		0.1	0.41
Long Term Debt	0.85	0.96	0.74	-0.56	0.82	0.83	-0.92	0.62	0.48	0.73	-0.57	0.8	0.81	0.5	0.82	0.99	0.11	0.97	0.9	0.86	0.85	0.93	0.63	0.1		0.81
Other Stockholder Equity	0.98	0.89	0.89	-0.02	0.95	0.57	-0.97	0.79	0.62	0.9	-0.37	0.73	0.97	0.82	0.96	0.83	0.34	0.87	0.94	0.97	0.97	0.74	0.64	0.41	0.81

Click cells to compare fundamentals

Alnylam Pharmaceuticals Account Relationship Matchups

Alnylam Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	2.4B	3.4B	3.6B	3.5B	3.8B	4.0B
Other Current Liab	206.5M	355.9M	395.2M	545.5M	713.0M	748.7M
Total Current Liabilities	956.4M	1.1B	1.2B	767.9M	967.8M	1.0B
Total Stockholder Equity	1.4B	1.0B	588.2M	(158.2M)	(220.6M)	(209.6M)
Property Plant And Equipment Net	646.4M	706.5M	733.6M	738.6M	725.8M	762.1M
Net Debt	(243.4M)	24.6M	177.6M	453.9M	1.9B	2.0B
Retained Earnings	(3.7B)	(4.6B)	(5.4B)	(6.6B)	(7.0B)	(6.7B)
Accounts Payable	49.9M	52.0M	73.4M	98.1M	55.5M	28.9M
Cash	547.2M	496.6M	820.0M	866.4M	812.7M	853.3M
Non Current Assets Total	661.2M	1.2B	774.5M	854.1M	847.2M	889.5M
Non Currrent Assets Other	18.1M	500M	40.9M	115.5M	(576.4M)	(547.6M)
Other Assets	32.9M	40.7M	101.1M	115.5M	132.8M	139.4M
Cash And Short Term Investments	1.5B	1.9B	2.4B	2.2B	2.4B	2.6B
Common Stock Shares Outstanding	109.3M	115.0M	118.5M	121.7M	124.9M	70.4M
Short Term Investments	989.0M	1.4B	1.6B	1.3B	1.6B	1.7B
Liabilities And Stockholders Equity	2.4B	3.4B	3.6B	3.5B	3.8B	4.0B
Non Current Liabilities Total	603.8M	1.3B	1.9B	2.9B	3.1B	3.2B
Other Current Assets	98.4M	625.5M	88.1M	132.9M	126.4M	94.5M
Total Liab	956.4M	2.4B	3.1B	3.7B	4.1B	4.3B
Property Plant And Equipment Gross	425.2M	706.5M	733.6M	738.6M	948.9M	996.3M
Total Current Assets	1.7B	2.2B	2.9B	2.7B	3.0B	3.1B
Accumulated Other Comprehensive Income	(36.5M)	(43.6M)	(33.3M)	(44.7M)	(23.4M)	(22.2M)
Property Plant Equipment	425.2M	465.0M	502.0M	523.5M	602.0M	632.1M
Short Long Term Debt Total	303.8M	521.2M	997.6M	1.3B	2.7B	2.8B
Other Liab	327.7M	352.3M	1.4B	406.4M	467.3M	490.7M
Current Deferred Revenue	396.2M	352.3M	301.8M	42.1M	102.8M	119.3M
Other Stockholder Equity	5.2B	5.6B	6.1B	6.5B	6.8B	7.2B
Short Term Debt	303.8M	50.2M	77.6M	82.3M	96.5M	101.3M
Net Receivables	43.0M	102.4M	198.6M	238.0M	327.8M	344.2M
Common Stock Total Equity	1.1M	1.2M	1.2M	1.2M	1.4M	770.9K
Common Stock	1.1M	1.2M	1.2M	1.2M	1.3M	801.6K
Net Tangible Assets	1.4B	1.0B	588.2M	(158.2M)	(182.0M)	(172.9M)
Retained Earnings Total Equity	(3.7B)	(4.6B)	(5.4B)	(6.6B)	(5.9B)	(5.6B)
Capital Surpluse	5.2B	5.6B	6.1B	6.5B	7.4B	7.8B
Inventory	56.3M	92.3M	122.7M	129.0M	89.1M	93.6M
Non Current Liabilities Other	603.8M	1.6B	1.7B	1.5B	1.6B	1.7B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Alnylam Stock Analysis

When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Alnylam Cost Of Revenue vs Capex To Revenue Analysis

Cost Of Revenue vs Capex To Revenue

Cost Of Revenue vs Capex To Revenue Correlation Analysis

Correlation Coefficient

Cost Of Revenue

Capex To Revenue

Alnylam Pharmaceuticals fundamental ratios Correlations

Alnylam Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Alnylam Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

Additional Tools for Alnylam Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Cash And Short Term Investments
Total Liab	+ 0.99	Non Current Liabilities Total
Long Term Debt	+ 0.99	Non Current Liabilities Total
Cash And Short Term Investments	+ 0.98	Total Assets
Other Stockholder Equity	+ 0.98	Total Assets

Property Plant Equipment	- 0.98	Retained Earnings
Property Plant And Equipment Gross	- 0.98	Retained Earnings
Other Stockholder Equity	- 0.97	Retained Earnings
Retained Earnings	- 0.97	Total Assets
Total Current Assets	- 0.96	Retained Earnings
Total Liab	- 0.96	Retained Earnings